Klein R J, Friedman-Kien A E, Brady E
Antimicrob Agents Chemother. 1974 Mar;5(3):318-22. doi: 10.1128/AAC.5.3.318.
A hairless mouse-herpes simplex virus skin infection experimental model was used to evaluate the efficacy of the antiviral compounds 9-beta-d-arabinofuranosyladenine (ara-A), 5-iodo-2'-deoxyuridine (IUdR), and 6-azauridine (aza-U). Ara-A and IUdR, when administered intraperitoneally by several different dosage schedules, reduced the severity of cutaneous herpetic lesions and the incidence of paralysis and increased significantly the number of survivors. A more rapid healing of the lesions and an increase in the mean survival time also was observed. A delay of 24 to 48 h in the initiation of treatment after the infection was more effective than treatments started at the time of inoculation. Treatment with ara-A was somewhat superior to that with IUdR, but aza-U was totally ineffective. Enhancement of the evolution of the infection was noted after treatment with aza-U.
使用无毛小鼠 - 单纯疱疹病毒皮肤感染实验模型来评估抗病毒化合物9-β-D-阿拉伯呋喃糖基腺嘌呤（阿糖腺苷，ara-A）、5-碘-2'-脱氧尿苷（碘苷，IUdR）和6-氮杂尿苷（氮杂尿苷，aza-U）的疗效。当通过几种不同的给药方案腹腔注射阿糖腺苷和碘苷时，可减轻皮肤疱疹病变的严重程度和麻痹的发生率，并显著增加存活小鼠的数量。还观察到病变愈合加快以及平均存活时间延长。感染后延迟24至48小时开始治疗比接种时开始治疗更有效。阿糖腺苷治疗在某种程度上优于碘苷治疗，但氮杂尿苷完全无效。用氮杂尿苷治疗后发现感染进展加快。
